-$0.18 EPS Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter

Equities research analysts predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will announce earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.19). Infinity Pharmaceuticals reported earnings per share of ($0.21) during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.3%. The company is scheduled to report its next earnings results on Tuesday, May 8th.

According to Zacks, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.74) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to ($0.70). For the next year, analysts expect that the business will report earnings of ($0.66) per share, with EPS estimates ranging from ($0.90) to ($0.53). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Infinity Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.11.



A number of large investors have recently bought and sold shares of INFI. JPMorgan Chase & Co. purchased a new position in Infinity Pharmaceuticals during the 3rd quarter valued at about $135,000. Clear Harbor Asset Management LLC purchased a new position in Infinity Pharmaceuticals during the 4th quarter valued at about $312,000. Alambic Investment Management L.P. purchased a new position in Infinity Pharmaceuticals during the 4th quarter valued at about $158,000. Wells Fargo & Company MN increased its holdings in Infinity Pharmaceuticals by 654.7% during the 4th quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock valued at $213,000 after acquiring an additional 91,206 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Infinity Pharmaceuticals by 22.2% during the 4th quarter. Geode Capital Management LLC now owns 325,567 shares of the biotechnology company’s stock valued at $660,000 after acquiring an additional 59,064 shares in the last quarter. Hedge funds and other institutional investors own 49.47% of the company’s stock.

Shares of INFI opened at $1.98 on Friday. The stock has a market capitalization of $97.17, a PE ratio of -2.39 and a beta of 2.48. Infinity Pharmaceuticals has a 52-week low of $0.93 and a 52-week high of $3.75.

TRADEMARK VIOLATION WARNING: This report was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://stocknewstimes.com/2018/04/25/0-18-eps-expected-for-infinity-pharmaceuticals-inc-infi-this-quarter.html.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply